Exelixis (EXEL) Competitors

Exelixis (NASDAQ:EXEL) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, institutional ownership, profitability, valuation, dividends, community ranking, earnings and risk.

Which has more volatility & risk, EXEL or ALNY?

Exelixis has a beta of 0.53, meaning that its stock price is 47% less volatile than the S&P 500. Comparatively, Alnylam Pharmaceuticals has a beta of 0.35, meaning that its stock price is 65% less volatile than the S&P 500.

Which has higher valuation and earnings, EXEL or ALNY?

Exelixis has higher earnings, but lower revenue than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exelixis	$2.17B	4.53	$521.27M	$1.77	19.82
Alnylam Pharmaceuticals	$2.25B	14.54	-$278.16M	-$2.17	-116.36

Do institutionals and insiders hold more shares of EXEL or ALNY?

85.3% of Exelixis shares are held by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. 2.9% of Exelixis shares are held by insiders. Comparatively, 1.5% of Alnylam Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Does the media prefer EXEL or ALNY?

In the previous week, Alnylam Pharmaceuticals had 11 more articles in the media than Exelixis. MarketBeat recorded 41 mentions for Alnylam Pharmaceuticals and 30 mentions for Exelixis. Exelixis' average media sentiment score of 0.56 beat Alnylam Pharmaceuticals' score of 0.40 indicating that Exelixis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exelixis	11 Very Positive mention(s)	1 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Alnylam Pharmaceuticals	18 Very Positive mention(s)	1 Positive mention(s)	9 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do analysts rate EXEL or ALNY?

Exelixis presently has a consensus target price of $37.24, suggesting a potential upside of 6.11%. Alnylam Pharmaceuticals has a consensus target price of $299.48, suggesting a potential upside of 18.61%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Alnylam Pharmaceuticals is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exelixis	1 Sell rating(s)	7 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.55
Alnylam Pharmaceuticals	1 Sell rating(s)	5 Hold rating(s)	19 Buy rating(s)	0 Strong Buy rating(s)	2.72

Is EXEL or ALNY more profitable?

Exelixis has a net margin of 24.04% compared to Alnylam Pharmaceuticals' net margin of -12.37%. Exelixis' return on equity of 23.52% beat Alnylam Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exelixis	24.04%	23.52%	17.95%
Alnylam Pharmaceuticals	-12.37%	N/A	-6.83%

Does the MarketBeat Community prefer EXEL or ALNY?

Alnylam Pharmaceuticals received 525 more outperform votes than Exelixis when rated by MarketBeat users. Likewise, 76.20% of users gave Alnylam Pharmaceuticals an outperform vote while only 68.59% of users gave Exelixis an outperform vote.

Company	Underperform	Outperform
Exelixis	Outperform Votes 618 68.59%	Underperform Votes 283 31.41%
Alnylam Pharmaceuticals	Outperform Votes 1143 76.20%	Underperform Votes 357 23.80%

Summary

Exelixis and Alnylam Pharmaceuticals tied by winning 9 of the 18 factors compared between the two stocks.